Nanologica AB (publ) (STO:NICA)
Sweden · Delayed Price · Currency is SEK 0.3990
+0.0080 (2.05%)
At close: Mar 4, 2026
Nanologica AB Revenue
In the year 2025, Nanologica AB had annual revenue of 21.05M SEK with 44.79% growth. Nanologica AB had revenue of 5.23M in the quarter ending December 31, 2025, a decrease of -22.07%.
Revenue
21.05M
Revenue Growth
+44.79%
P/S Ratio
1.67
Revenue / Employee
1.11M
Employees
19
Market Cap
35.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.05M | 6.51M | 44.79% |
| Dec 31, 2024 | 14.54M | 9.87M | 211.17% |
| Dec 31, 2023 | 4.67M | -1.16M | -19.92% |
| Dec 31, 2022 | 5.83M | -8.91M | -60.43% |
| Dec 31, 2021 | 14.75M | -3.59M | -19.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alzinova AB | 26.12M |
| Fluicell AB | 15.22M |
| ExpreS2ion Biotech Holding AB | 10.85M |
| AcouSort AB | 10.43M |
| Spago Nanomedical AB | 4.82M |
| OncoZenge AB | 2.78M |
| Aptahem AB | 2.59M |
| 2cureX AB | 1.98M |